Amicus Therapeutics Stock Analysis

Amicus Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.04. Amicus Therapeutics last dividend was issued on the 31st of August 2009. Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Amicus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 496 people. To learn more about Amicus Therapeutics call Bradley MBA at 609 662 2000 or check out https://amicusrx.com.

Amicus Therapeutics Investment Alerts

Amicus Largest EPS Surprises

View All Earnings Estimates

Amicus Therapeutics Environmental, Social, and Governance (ESG) Scores

Amicus Stock Institutional Investors

Note, although Amicus Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Amicus Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.5 B.

Amicus Profitablity

The company has Profit Margin (PM) of (0.02) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.2 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.2.

Management Efficiency

Amicus Therapeutics has return on total asset (ROA) of 0.0261 % which means that it generated a profit of $0.0261 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0687) %, meaning that it created substantial loss on money invested by shareholders. Amicus Therapeutics' management efficiency ratios could be used to measure how well Amicus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.04, whereas Return On Tangible Assets are forecasted to decline to (0.09). At present, Amicus Therapeutics' Intangibles To Total Assets are projected to slightly decrease based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.53, whereas Other Assets are forecasted to decline to about 41.8 M.

Technical Drivers

As of the 19th of February, Amicus Therapeutics shows the Mean Deviation of 1.38, risk adjusted performance of 0.1513, and Coefficient Of Variation of 552.12. Amicus Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Amicus Therapeutics treynor ratio, and the relationship between the variance and potential upside to decide if Amicus Therapeutics is priced correctly, providing market reflects its regular price of 14.35 per share. Given that Amicus Therapeutics has treynor ratio of 2.32, we suggest you to validate Amicus Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Amicus Therapeutics Price Movement Analysis

Amicus Therapeutics Insider Trading Activities

Amicus Therapeutics Outstanding Bonds

Amicus Therapeutics Predictive Daily Indicators

Amicus Therapeutics Corporate Filings

Amicus Therapeutics Forecast Models

Amicus Therapeutics' time-series forecasting models are one of many Amicus Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Amicus Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Amicus Therapeutics Bond Ratings

Amicus Therapeutics financial ratings play a critical role in determining how much Amicus Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Amicus Therapeutics' borrowing costs.

Amicus Therapeutics Debt to Cash Allocation

Amicus Therapeutics currently holds 443.64 M in liabilities with Debt to Equity (D/E) ratio of 2.6, implying the company greatly relies on financing operations through barrowing. Amicus Therapeutics has a current ratio of 2.96, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Amicus Therapeutics' use of debt, we should always consider it together with its cash and equity.

Amicus Therapeutics Total Assets Over Time

Amicus Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Amicus Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Amicus Therapeutics Debt Ratio

53.0

It looks as if about 47% of Amicus Therapeutics' assets are financed be debt. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Amicus Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Amicus Therapeutics, which in turn will lower the firm's financial flexibility.

Amicus Therapeutics Corporate Bonds Issued

Amicus Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Amicus Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Amicus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Amicus Therapeutics. By using and applying Amicus Stock analysis, traders can create a robust methodology for identifying Amicus entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Amicus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Amicus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Amicus Therapeutics stock analysis indicators help investors evaluate how Amicus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Amicus Therapeutics shares will generate the highest return on investment. By understating and applying Amicus Therapeutics stock analysis, traders can identify Amicus Therapeutics position entry and exit signals to maximize returns.

When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.